12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Somatoprim: Phase IIa data

Top-line data from an open-label, Ukrainian Phase IIa trial in about 20 treatment-naïve patients with acromegaly showed that single ascending-doses of subcutaneous Somatoprim dose-dependently reduced hGH secretion. No serious adverse events were reported. Aspireo said it determined the recommended dosing for further clinical testing, but...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >